Maravai LifeSciences Sees Unusually Large Options Volume (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) was the target of some unusual options trading on Wednesday. Traders bought 1,002 put options on the company. This represents an increase of 1,791% compared to the typical volume of 53 put options.

Hedge Funds Weigh In On Maravai LifeSciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MRVI. Jane Street Group LLC boosted its stake in Maravai LifeSciences by 1,463.1% during the first quarter. Jane Street Group LLC now owns 380,403 shares of the company’s stock worth $841,000 after buying an additional 356,067 shares during the last quarter. Creative Planning boosted its stake in Maravai LifeSciences by 49.6% during the second quarter. Creative Planning now owns 116,031 shares of the company’s stock worth $280,000 after buying an additional 38,450 shares during the last quarter. Rhumbline Advisers boosted its stake in Maravai LifeSciences by 20.3% during the second quarter. Rhumbline Advisers now owns 195,272 shares of the company’s stock worth $471,000 after buying an additional 32,940 shares during the last quarter. Prudential Financial Inc. acquired a new position in Maravai LifeSciences during the second quarter worth $36,000. Finally, Invesco Ltd. boosted its stake in Maravai LifeSciences by 16.8% during the second quarter. Invesco Ltd. now owns 282,192 shares of the company’s stock worth $680,000 after buying an additional 40,495 shares during the last quarter. Institutional investors and hedge funds own 50.25% of the company’s stock.

Maravai LifeSciences Stock Performance

Shares of NASDAQ:MRVI opened at $3.50 on Thursday. The company has a debt-to-equity ratio of 0.85, a current ratio of 6.60 and a quick ratio of 5.69. The business’s 50 day moving average price is $3.17 and its 200-day moving average price is $3.35. The firm has a market capitalization of $899.75 million, a PE ratio of -3.89 and a beta of 0.43. Maravai LifeSciences has a 1 year low of $1.66 and a 1 year high of $4.11.

Maravai LifeSciences (NASDAQ:MRVI) last issued its quarterly earnings results on Wednesday, February 25th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.03. The firm had revenue of $49.87 million for the quarter, compared to analyst estimates of $49.06 million. Maravai LifeSciences had a negative return on equity of 22.79% and a negative net margin of 70.40%. As a group, equities research analysts expect that Maravai LifeSciences will post -0.24 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded Maravai LifeSciences from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $5.38.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.